We propose to establish the UNC Interdisciplinary Program in Breast Cancer Research to serve as a national Specialized Program of Research Excellence (SPORE) in Breast Cancer for the National Cancer Institute. The UNC SPORE will have a unique set of goals, objectives, and programs that capitalize on and extend in novel ways the existing excellence in multidisciplinary breast cancer research at UNC and the UNC Lineberger Comprehensive Cancer Center. The goal of the UNC SPORE is to reduce breast cancer mortality and incidence in North Carolina through an interdisciplinary program of research and intervention that: 1. Integrates efforts in cancer prevention and control, molecular epidemiology, clinical research, and laboratory clinical research; and 2. Targets behavioral and biological issues relevant to Black women. The six primary objectives of the UNC SPORE are: 1. To identify the determinants of the Black/White gap in breast cancer mortality in North Carolina, and then to use novel community and provider interventions to close that gap; 2. To initiate a long-term, population-based study of breast cancer in a defined North Carolina population containing 1.6 million women, 27% of whom are minorities; 3. To combine molecular biology and epidemiology in the investigation of the environmental determinants of and genetic predispositions to breast cancer in blacks and whites in the defined population; 4. To improve the treatment, quality-of-life, and prognosis of late-stage breast cancer, a common presentation among Black women in North Carolina; 5. To develop new clinical markers for neoplastic proliferation of breast cancer cells; and 6. To complement the NCI and other SPOREs in the national effort to reduce breast cancer mortality and incidence with a focus on minority issues, development of a defined population, and research programs in cancer prevention and control, molecular epidemiology, clinical research, and the isolation and molecular analysis of novel regulatory genes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058223-03
Application #
2098928
Study Section
Special Emphasis Panel (SRC (50))
Project Start
1992-09-30
Project End
1995-09-29
Budget Start
1994-09-30
Budget End
1995-09-29
Support Year
3
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Mundt, Filip; Rajput, Sandeep; Li, Shunqiang et al. (2018) Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers. Cancer Res 78:2732-2746
Takaku, Motoki; Grimm, Sara A; Roberts, John D et al. (2018) GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network. Nat Commun 9:1059
Butler, Eboneé N; Bensen, Jeannette T; Chen, Mengjie et al. (2018) Prediagnostic Smoking Is Associated with Binary and Quantitative Measures of ER Protein and ESR1 mRNA Expression in Breast Tumors. Cancer Epidemiol Biomarkers Prev 27:67-74
Echavarria, Isabel; López-Tarruella, Sara; Picornell, Antoni et al. (2018) Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification. Clin Cancer Res 24:1845-1852
Cai, Ling; Tsai, Yi-Hsuan; Wang, Ping et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Mol Cell 72:341-354.e6
Bensen, Jeannette T; Graff, Mariaelisa; Young, Kristin L et al. (2018) A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women. Breast Cancer Res 20:45
Puvanesarajah, Samantha; Nyante, Sarah J; Kuzmiak, Cherie M et al. (2018) PAM50 and Risk of Recurrence Scores for Interval Breast Cancers. Cancer Prev Res (Phila) 11:327-336
Knott, Simon R V; Wagenblast, Elvin; Khan, Showkhin et al. (2018) Asparagine bioavailability governs metastasis in a model of breast cancer. Nature 554:378-381
McRee, Autumn J; Marcom, Paul K; Moore, Dominic T et al. (2018) A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer. Clin Breast Cancer 18:289-297
DeBono, Nathan L; Robinson, Whitney R; Lund, Jennifer L et al. (2018) Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study. J Womens Health (Larchmt) 27:377-386

Showing the most recent 10 out of 598 publications